<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821297</url>
  </required_header>
  <id_info>
    <org_study_id>20D.1271</org_study_id>
    <nct_id>NCT04821297</nct_id>
  </id_info>
  <brief_title>Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results</brief_title>
  <official_title>An Innovative and Linguistically-Tailored Mobile Intervention to Improve Follow-Up for Abnormal Pap Test Results: CervixChat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates the feasibility of a linguistically-tailored mobile&#xD;
      intervention, called CervixChat in improving the follow-up of patients with abnormal&#xD;
      Papanicolaou (pap) test results. A text messaging program, such as CervixChat may support&#xD;
      patients who need a colposcopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the feasibility of CervixChat intervention in a mix method design, through&#xD;
      participants consent rate and the study completion rate.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the acceptability of CervixChat intervention using a validated Likert-scale&#xD;
      participant satisfaction questionnaire, as well as participant's interview data.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the preliminary impact of CervixChat intervention, by comparing the colposcopy&#xD;
      appointment adherence rate in the study cohort against a 1:1 matched control sample selected&#xD;
      based on matching age, race and ethnicity, from participants at Jefferson Obstetrics and&#xD;
      Gynecology (Ob-Gyn) department scheduled for a colposcopy in 2019.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive text messages for 1-2 months before scheduled appointment. Patients also&#xD;
      complete a survey at baseline and after standard of care colposcopy and an interview after&#xD;
      standard of care colposcopy.&#xD;
&#xD;
      After completion of study, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Consent Rate</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Completion Rate</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Supportive care (message)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health Promotion and Education</intervention_name>
    <description>Receive messages</description>
    <arm_group_label>Supportive care (message)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Complete survey</description>
    <arm_group_label>Supportive care (message)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Participate in an interview</description>
    <arm_group_label>Supportive care (message)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, aged 21 to 65 years of age&#xD;
&#xD;
          -  Had received an abnormal Pap smear result&#xD;
&#xD;
          -  Scheduled colposcopy&#xD;
&#xD;
          -  Able to communicate with ease in English or Spanish&#xD;
&#xD;
          -  Have a cell phone with text (TXT) ability&#xD;
&#xD;
          -  Competent to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant at the time of recruitment&#xD;
&#xD;
          -  Display current evidence of positive invasive carcinoma of the cervix&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuang-Yi Wen, MD</last_name>
      <phone>215-503-4623</phone>
      <email>Kuang-Yi.Wen@Jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

